Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$41.92M+4699.39%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jon R. Levine
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 866
- Beta
- 1.36
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -0.08
Financials
Revenue
$41.92M+4699.4%Net Income
$-3.59MEBITDA
$3.58M+2849.1%Free Cash Flow
$1.92MEPS (diluted)
$-0.01Shares Outstanding (diluted)
399.60M+523.6%Operating Expenses
$7.71MCash & Debt
$8.44MReturn of Capital
$49.0KRevenue by Segment (annual)
$159.83MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $159.83M | $-14.48M | $-0.04 |
| 2024 | $157.96M | $-12.16M | $-0.03 |
| 2023 | $148.60M | $-16.03M | $-0.04 |
| 2022 | $134.01M | $13.47M | $0.04 |
| 2021 | $121.46M | $7.22M | $0.02 |
| 2020 | $50.90M | $2.14M | $0.01 |
| 2019 | $45.60M | $-66.52M | $-0.32 |
| 2018 | $11.85M | $-13.60M | $-0.07 |
| 2017 | $6.07M | $-1.19M | $-0.01 |
| 2016 | $3.56M | $-198.9K | $-0.00 |
| 2015 | $1.27M | $-1.22M | $-0.04 |
| 2014 | $88.4K | $-7.22M | $-0.23 |
| 2013 | $904.00 | $-535.6K | $-0.02 |
| 2012 | $785.00 | $-809.5K | $-0.04 |
Valuation
MRMDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·12d ago·Neutral
MariMed's Betty's Eddies Spreads Importance of Cancer Screening Education and Awareness this October through Partnership with Keep A Breast Foundation MariMed's Betty's Eddies Spreads Importance of Cancer Screening Education and Awareness this October through Partnership with Keep A Breast Foundation
View source ↗ - Newsglobenewswire.com·13d ago·Negative
…al Meeting of Stockholders to Approve Proposed Reverse Stock Split NORWOOD, Mass., Sept. 23, 2026 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQB: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced that it has filed a definitive proxy statement with the U.S. Securities and Exchange Commission (“SEC”) in connection with a Special Meeting of Stockholders (the “Special Meeting”) to seek stockholder approval of a prop…
View source ↗ - Newsglobenewswire.com·19d ago·Neutral
MariMed Announces Thrive Wellness Dispensary Opening in Columbus, Ohio NORWOOD, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQB: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced the September 18th opening of Thrive Dispensary Columbus, the Company's 14th Thrive Dispensary location in five states and its second in Ohio.
View source ↗ - Newsseekingalpha.com·53d ago·Positive
MariMed Inc. (MRMD) Q2 2026 Earnings Call Transcript MariMed Inc. (MRMD) Q2 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
MariMed Reports Second Quarter 2026 Earnings NORWOOD, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQB: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the second quarter ended June 30, 2026.
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-0.01 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.01 vs $-0.01beat
- Wed, May 13$-0.01 vs $-0.01beat
- Wed, Mar 11$0.01 vs $-0.01beat
- Wed, Nov 5$-0.01 vs $-0.01beat
- Wed, Aug 6$-0.00 vs $-0.01beat
- Wed, May 7$-0.01 vs $-0.01beat
Estimates and results for MRMD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MRMD officers and directors.
- Bought
- $7k
- Sold
- —
4 trades
0 trades
- Levine Jon Rbought
- Levine Jon Rbought
- Levine Jon Rbought
- Levine Jon Rbought
96 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MRMD.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.